Insmed (INSM) Stock Price, News & Analysis

$24.77
-0.33 (-1.31%)
(As of 05/17/2024 ET)
Today's Range
$24.38
$25.11
50-Day Range
$24.11
$28.56
52-Week Range
$18.31
$32.00
Volume
2.59 million shs
Average Volume
1.76 million shs
Market Capitalization
$3.68 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.71

Insmed MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
80.5% Upside
$44.71 Price Target
Short Interest
Healthy
5.74% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.29
Upright™ Environmental Score
News Sentiment
0.47mentions of Insmed in the last 14 days
Based on 31 Articles This Week
Insider Trading
Selling Shares
$1.18 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.56) to ($3.68) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.52 out of 5 stars

Medical Sector

97th out of 923 stocks

Pharmaceutical Preparations Industry

33rd out of 425 stocks

INSM stock logo

About Insmed Stock (NASDAQ:INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

INSM Stock Price History

INSM Stock News Headlines

Insmed (NASDAQ:INSM) PT Raised to $49.00
HC Wainwright Reiterates Buy Rating for Insmed (NASDAQ:INSM)
Insmed (NASDAQ:INSM) PT Raised to $36.00 at Mizuho
Insmed (NASDAQ:INSM) Lifted to Hold at StockNews.com
Insmed (INSM) Receives a Buy from Stifel Nicolaus
Insmed Sees Unusually High Options Volume (NASDAQ:INSM)
This Is What Whales Are Betting On Insmed
Here's what to expect from Insmed's earnings
See More Headlines
Receive INSM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
5/17/2024
Next Earnings (Estimated)
8/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INSM
Employees
373
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.71
High Stock Price Target
$55.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+80.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
14 Analysts

Profitability

Net Income
$-749,570,000.00
Net Margins
-236.74%
Pretax Margin
-235.89%

Debt

Sales & Book Value

Annual Sales
$305.21 million
Book Value
($3.13) per share

Miscellaneous

Free Float
141,769,000
Market Cap
$3.68 billion
Optionable
Optionable
Beta
0.93

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

INSM Stock Analysis - Frequently Asked Questions

Should I buy or sell Insmed stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INSM shares.
View INSM analyst ratings
or view top-rated stocks.

What is Insmed's stock price target for 2024?

14 brokers have issued 1-year target prices for Insmed's stock. Their INSM share price targets range from $36.00 to $55.00. On average, they predict the company's stock price to reach $44.71 in the next twelve months. This suggests a possible upside of 80.5% from the stock's current price.
View analysts price targets for INSM
or view top-rated stocks among Wall Street analysts.

How have INSM shares performed in 2024?

Insmed's stock was trading at $30.99 on January 1st, 2024. Since then, INSM shares have decreased by 20.1% and is now trading at $24.77.
View the best growth stocks for 2024 here
.

When is Insmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024.
View our INSM earnings forecast
.

How were Insmed's earnings last quarter?

Insmed Incorporated (NASDAQ:INSM) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($1.06) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.16. The biopharmaceutical company earned $75.50 million during the quarter, compared to analyst estimates of $77.76 million. The company's quarterly revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.17) EPS.

What guidance has Insmed issued on next quarter's earnings?

Insmed issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $340.0 million-$360.0 million, compared to the consensus revenue estimate of $353.5 million.

What is Will Lewis' approval rating as Insmed's CEO?

14 employees have rated Insmed Chief Executive Officer Will Lewis on Glassdoor.com. Will Lewis has an approval rating of 78% among the company's employees.

What other stocks do shareholders of Insmed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include Gilead Sciences (gild), AbbVie (ABBV), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA) and Geron (GERN).

Who are Insmed's major shareholders?

Insmed's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.77%), Price T Rowe Associates Inc. MD (7.25%), William Blair Investment Management LLC (2.84%), Bellevue Group AG (1.44%), Capital International Investors (1.09%) and Principal Financial Group Inc. (0.97%). Insiders that own company stock include David R Brennan, John Drayton Wise, Martina MD Flammer, Melvin Md Sharoky, Michael Alexander Smith, Orlov S Nicole Schaeffer, Roger Adsett, Sara Bonstein and William Lewis.
View institutional ownership trends
.

How do I buy shares of Insmed?

Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INSM) was last updated on 5/18/2024 by MarketBeat.com Staff

From Our Partners